Gene-expression signatures differ between different clinical forms of familial hemophagocytic lymphohistiocytosis

Blood

Volumn 121, Issue 7, 2013, Pages

  Sumegi, Janos ^a   Nestheide, Shawnagay V ^a   Barnes, Michael G ^a   Villanueva, Joyce ^a   Zhang, Kejian ^a   Grom, Alexei A ^a   Filipovich, Alexandra H ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ZINC;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL DIFFERENTIATION; CELL SURVIVAL; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC VARIABILITY; HEMOPHAGOCYTIC SYNDROME; HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFANT; INFLAMMATION; LANGHANS GIANT CELL; MAJOR CLINICAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; RELAPSE; SCHOOL CHILD; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UPREGULATION;

EID: 84874100105     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-05-425769     Document Type: Article

References (48)

1. Filipovich AH. Hemophagocytic lymphohistiocyto-sis and other hemophagocytic disorders. Immunol Allergy Clin North Am. 2008;28(2):293-313.
2. Ohadi M, Lalloz MR, Sham P, et al. Localization of a gene for familial hemophagocytic lymphohis-tiocytosis at chromosome 9q21. 3-22 by homozy-gosity mapping. Am J Hum Genet. 1999;64(1): 165-171. (Pubitemid 30428969)
3. Dufourcq-Lagelouse R, Jabado N, Le Deist, et al. Linkage of familial hemophagocytic lymphohistio-cytosis to 10q21-22 and evidence for heterogeneity. Am J Hum Genet. 1999;64(1):172-179. (Pubitemid 30428970)
4. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 1999;286(5446): 1957-1959. (Pubitemid 129515904)
5. Kogawa K, Lee SM, Villanueva J, et al. Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood. 2002;99(1):61-66.
6. Feldmann J, Callebaut I, Raposo G, et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophago-cytic lymphohistiocytosis (FHL3). Cell. 2003; 115(4):461-473. (Pubitemid 37456808)
7. zur Stadt U, Schmidt S, Kasper B, et al. Linkage of familial hemophagocytic lymphohistiocytosis (FHLH) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum Mol Genet. 2005;14(6):827-834. (Pubitemid 40403278)
8. zur Stadt U, Rohr J, Seifert W, et al. Familial he-mophagocytic lymphohistiocytosis type 5 (FHLH-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11. Am J Hum Genet. 2009; 85(4):482-892.
9. Jordan MB, Allen CE, Weitzman S, et al. How we treat hemophagocytic lymphohistocytosis. Blood. 2011;118(15):4041-4052.
10. Henter JI, Andersson B, Elinder G, et al. Elevated circulating levels of interleukin-1 receptor antagonist but not IL-1 agonists in hemophagocytic lym-phohistiocytosis. Med Pediatr Oncol. 1996;27(1): 21-25. (Pubitemid 26144180)
11. Zhang K, Jordan MB, Marsh RA, et al. Hypomor-phic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. Blood. 2011;118(22):5794-5798.
12. Henter JI, Arico M, Egeler M, et al. HLH-94: A treatment protocol for hemophagocytic lympho-histiocytosis. Med Pediatr Oncol. 1997;28(5):342-347. (Pubitemid 27163671)
13. Henter JI, Horne A, Aricó M, et al. HLH-2004: Diagnostic and therapeutic guidelines for he-mophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131. (Pubitemid 44958267)
14. Lin TF, Ferlic-Stark LL, Allen CE, et al. Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality. Pediatr Blood Cancer. 2011;56(1):154-155.
15. Sumegi J, Barnes MG, Nestheide SV, et al. Gene expression profiling of peripheral blood mononu-clear cells from children with active hemophago-cytic lymphohistiocytosis. Blood. 2011;117(15): e151-e160.
16. Dennis G Jr., Sherman BT, Hosack DA, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003; 4(5):P3.
17. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Pro-toc. 2009;4(1):44-57.
18. Ogilvie EM, Khan A, Hubank M, et al. Specific gene expression profiles in systemic juvenile idio-pathic arthritis. Arthritis Rheum. 2007;56(6):1954-1965. (Pubitemid 47110394)
19. Molleran Lee S, Villanueva J, Sumegi J, et al. Characterisation of diverse PRF1 mutations leading to decreased natural killer cell activity in North American families with haemophagocytic lympho-histiocytosis. J Med Genet. 2004;41(2):137-144. (Pubitemid 38221753)
20. Janka GE. Familial and acquired hemophago-cytic lymphohistiocytosis. Eur J Pediatr. 2007; 166(2):95-109.
21. Risma KA, Frayer RW, Filipovich AH, et al. Aberrant maturation of mutant perforin underlies the clinical diversity of hemophagocytic lymphohistio- cytosis. J Clin Invest. 2006;116(1):182-192. (Pubitemid 43121803)
22. Lehrer RI, Ganz T. Defensins of vertebrate animals. Curr Opin Immunol. 2002;14(1):96-102. (Pubitemid 34085112)
23. Funderburg N, Lederman MM, Feng Z et al. Human-defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2. Proc Nat Acad Sci USA. 2007;104(47):18631-18635. (Pubitemid 350210748)
24. Sasaki T, Knyazev PG, Clout NJ, et al. Structural basis for Gas6-Axl signaling. EMBO J. 2006; 25(1):80-87.
25. Zhao R, Goldman ID. Resistance to antifolates. Oncogene. 2003;22(47):7431-7457. (Pubitemid 37487168)
26. Kager L, Cheok M, Yang W, et al. Folate pathway gene expression differs in subtypes of acute lym-phoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest. 2005;115(1): 110-117. (Pubitemid 40385511)
27. Tsukazaki T, Chiang TA, Davison AF, et al. SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell. 1998;95(6):779-791. (Pubitemid 29014458)
28. Hu Y, Chuang JZ, Xu K, et al. SARA, a FYVE domain protein, affects Rab5-mediated endocytosis. J Cell Sci. 2002;115(24):4755-4763. (Pubitemid 36067290)
29. Heeger PS, Lalli PN, Lin F, et al. Decay-accelerating factor modulates induction of T cell immunity. J Exp Med. 2005;201(10):1523-1530. (Pubitemid 40720998)
30. Sawka-Verhelle D, Escoubet-Lozach L, Fong AL, et al. PE-1/METS, an antiproliferative Ets repres-sor factor, is induced by CREB-1/CREM-1 during macrophage differentiation. J Biol Chem. 2004; 279(17):17772-17784. (Pubitemid 38560544)
31. Klappacher GW, Lunyak VV, Sykes DB, et al. An induced Ets repressor complex regulates growth arrest during terminal macrophage differentiation. Cell. 2002;109(2):169-180. (Pubitemid 34518256)
32. El Kasmi KC, Smith AM, Williams L, et al. Cutting edge: A transcriptional repressor and corepressor induced by the STAT3-regulated anti-inflammatory signaling pathway. J Immunol. 2007;179(11):7215-7219.
33. Côté JF, Vuori K. GEF what? Dock180 and related proteins help Rac to polarize cells in new ways. Trends Cell Biol. 2007;17(8):383-393. (Pubitemid 47375099)
34. Randall KL, Chan SS, Ma CS, et al. DOCK8 deficiency impairs CD8 T cell survival and function in humans and mice. J Exp Med. 2011;208(11): 2305-2320.
35. Hertz AL, Beavo JA. Cyclic nucleotides and phos-phodiesterases in monocytic differentiation. Handb Exp Pharmacol. 2011;204:365-390.
36. Hertz AL, Bender AT, Smith KC, et al. Elevated cyclic AMP and PDE4 inhibition induce chemo-kine expression in human monocyte-derived macrophages. Proc Natl Acad Sci USA. 2009; 106(51):21978-21983.
37. Cetica V, Santoro A, Gilmour KC, S et al. STXBP2 mutations in children with familial haemophagocytic lymphohistiocytosis type 5. J Med Genet. 2010; 47(9):595-600.
38. Stamm O, Krücken J, Schmitt-Wrede HP, et al. Human ortholog to mouse gene imap38 encoding an ER-localizable G-protein belongs to a gene family clustered on chromosome 7q32-36. Gene. 2002;282(1-2):159-167.
39. Barnes MJ, Aksoylar H, Krebs P, et al. Loss of T cell and B cell quiescence precedes the onset of microbial flora-dependent wasting disease and intestinal inflammation in Gimap5-deficient mice. J Immunol. 2010;184(7):3743-3754.
40. Schulteis RD, Chu H, Dai X, et al. Impaired survival of peripheral T cells, disrupted NK/NKT cell development, and liver failure in mice lacking Gimap5. Blood. 2008;112(13):4905-4914.
41. Saunders A, Webb LM, Janas ML, et al. Putative GTPase GIMAP1 is critical for the development of mature B and T lymphocytes. Blood. 2010; 115(16):3249-3257.
42. Filén JJ, Filén S, Moulder R, et al. Quantitative proteomics reveals GIMAP family proteins 1 and 4 to be differentially regulated during human T helper cell differentiation. Mol Cell Proteomics. 2009;8(1):32-44.
43. Yokooji Y, Tomita H, Atomi H, Imanaka T. Pantoate kinase and phosphopantothenate synthetase, two novel enzymes necessary for CoA biosynthesis in the archaea. J Biol Chem. 2009; 284(41):28137-28145.
44. Musso A, Zocchi MR, Poggi A. Relevance of the mevalonate biosynthetic pathway in the regulation of bone marrow mesenchymal stromal cell-mediated effects on T-cell proliferation and B-cell survival. Haematologica. 2011;96(1):16-23.
45. Kang CB, Hong Y, Dhe-Paganon S, Yoon HS. FKBP family proteins: immunophilins with versatile biological functions. Neurosignals. 2008; 16(4):318-25.
46. Li L, Lou Z, Wang L. The role of FKBP5 in cancer aetiology and chemoresistance. Br J Cancer. 2011;104(1):19-23.
47. Quintá HR, Galigniana NM, Erlejman AG, et al. Management of cytoskeleton architecture by molecular chaperones and immunophilins. Cell Signal. 2011;23(12):1907-1920.
48. Hanna J, Bechtel P, Zhai Y, et al. Novel insights on human NK cells' immunological modalities revealed by gene expression profiling. J Immunol. 2004;173(11):6547-6563. (Pubitemid 39541038)